2018
T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, McCarthy T, Zhang L, Gray D, Villalobos A, Lee C, Chen J, Seibyl J, Marek K. T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN. Schizophrenia Bulletin 2018, 44: s176-s176. PMCID: PMC5888516, DOI: 10.1093/schbul/sby016.432.Peer-Reviewed Original ResearchLogan graphical analysisNon-human primatesRhesus monkeysD1 receptorsBlockade studiesPET studiesPET radiotracersD1 receptor occupancyWhole-brain uptakeNovel PET radiotracersInhibitory G proteinSame dose levelMin post injectionHealthy human volunteersTest-retest reproducibilityBrain PET studiesPET imaging tracerAgonist PET tracerClinical studiesStriatal regionsInjected dosePsychiatric disordersCerebellar cortexDose levelsReceptor occupancy
2015
Imaging Studies with A2A Receptor Antagonists
Tavares A, Barret O, Seibyl J, Tamagnan G. Imaging Studies with A2A Receptor Antagonists. Current Topics In Neurotoxicity 2015, 10: 207-232. DOI: 10.1007/978-3-319-20273-0_11.Peer-Reviewed Original ResearchPositron emission tomographyValue of PETA2A receptor antagonistsSingle photon emissionPathophysiological progressionReceptor antagonistClinical studiesDifferential diagnosisParkinson's diseaseIodine-123Imaging studiesEmission tomographyNeuropsychiatric disordersSPECT probeSPECT techniqueSPECT radiotracerPET imagingA2AVivo characteristicsBrainSPECTPhoton emissionVivo propertiesRadiotracerRecent reports